$1.21 EPS Expected for Albemarle Co. (ALB) This Quarter

Equities research analysts forecast that Albemarle Co. (NYSE:ALB) will post earnings of $1.21 per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Albemarle’s earnings, with estimates ranging from $1.17 to $1.27. Albemarle reported earnings per share of $0.78 in the same quarter last year, which indicates a positive year-over-year growth rate of 55.1%. The company is scheduled to issue its next earnings report after the market closes on Tuesday, February 27th.

According to Zacks, analysts expect that Albemarle will report full year earnings of $4.46 per share for the current year, with EPS estimates ranging from $4.42 to $4.52. For the next financial year, analysts expect that the firm will report earnings of $5.16 per share, with EPS estimates ranging from $4.90 to $5.40. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Albemarle.

Albemarle (NYSE:ALB) last posted its quarterly earnings results on Wednesday, November 8th. The specialty chemicals company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.01. Albemarle had a net margin of 30.07% and a return on equity of 11.61%. The company had revenue of $755.00 million during the quarter, compared to analyst estimates of $732.19 million. During the same period last year, the firm posted $0.91 EPS. Albemarle’s revenue for the quarter was up 15.4% compared to the same quarter last year.

A number of research firms have issued reports on ALB. UBS Group raised their price target on shares of Albemarle from $123.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, November 9th. Jefferies Group reissued a “buy” rating on shares of Albemarle in a research report on Tuesday, October 24th. BMO Capital Markets started coverage on shares of Albemarle in a report on Tuesday, October 24th. They set an “outperform” rating and a $160.00 target price for the company. Zacks Investment Research lowered shares of Albemarle from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Finally, Goldman Sachs Group lowered shares of Albemarle from a “buy” rating to a “neutral” rating and lifted their target price for the company from $139.66 to $142.00 in a report on Friday, October 6th. Ten equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Albemarle has a consensus rating of “Buy” and a consensus price target of $127.78.

Albemarle (ALB) traded down $1.90 on Friday, reaching $116.01. 4,261,240 shares of the company’s stock were exchanged, compared to its average volume of 1,430,000. Albemarle has a 12 month low of $90.35 and a 12 month high of $144.99. The company has a quick ratio of 1.56, a current ratio of 2.11 and a debt-to-equity ratio of 0.35. The stock has a market cap of $12,610.00, a price-to-earnings ratio of 41.43, a PEG ratio of 1.55 and a beta of 1.69.

The business also recently declared a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 15th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 1.10%. The ex-dividend date of this dividend was Thursday, December 14th. Albemarle’s payout ratio is presently 45.71%.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Scotia Capital Inc. increased its holdings in Albemarle by 0.5% in the 2nd quarter. Scotia Capital Inc. now owns 2,022 shares of the specialty chemicals company’s stock worth $213,000 after acquiring an additional 10 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in Albemarle by 2.1% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 968 shares of the specialty chemicals company’s stock worth $102,000 after acquiring an additional 20 shares in the last quarter. L & S Advisors Inc increased its holdings in Albemarle by 2.2% in the 2nd quarter. L & S Advisors Inc now owns 4,200 shares of the specialty chemicals company’s stock worth $443,000 after acquiring an additional 90 shares in the last quarter. Thrivent Financial For Lutherans increased its holdings in Albemarle by 2.2% in the 2nd quarter. Thrivent Financial For Lutherans now owns 4,240 shares of the specialty chemicals company’s stock worth $447,000 after acquiring an additional 90 shares in the last quarter. Finally, Zacks Investment Management increased its holdings in Albemarle by 2.4% in the 2nd quarter. Zacks Investment Management now owns 4,767 shares of the specialty chemicals company’s stock worth $503,000 after acquiring an additional 111 shares in the last quarter. 88.07% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “$1.21 EPS Expected for Albemarle Co. (ALB) This Quarter” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/20/1-21-eps-expected-for-albemarle-co-alb-this-quarter.html.

Albemarle Company Profile

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Get a free copy of the Zacks research report on Albemarle (ALB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply